BRPI0613357A2 - peptídeo, segmento amino- e/ou carboxila truncado do peptídeo, sequência de nucleotídeos, vetor de expressão, célula hospedeira, proteína de fusão, preparação farmaceuticamente pura, composição, método para estabilização da placa aterosclerótica e redução da ocorrência de eventos de ruptura de placa, método de redução de inflamação e de deposição de lipídeo e aumento de deposição de colágeno e elastina dentro da lesão intima, método de ativação de tgf-b1 e/ou desativação de mmm-9 e método para a modulação da atividade de tgf-b1 e/ou mmm-9 - Google Patents

peptídeo, segmento amino- e/ou carboxila truncado do peptídeo, sequência de nucleotídeos, vetor de expressão, célula hospedeira, proteína de fusão, preparação farmaceuticamente pura, composição, método para estabilização da placa aterosclerótica e redução da ocorrência de eventos de ruptura de placa, método de redução de inflamação e de deposição de lipídeo e aumento de deposição de colágeno e elastina dentro da lesão intima, método de ativação de tgf-b1 e/ou desativação de mmm-9 e método para a modulação da atividade de tgf-b1 e/ou mmm-9

Info

Publication number
BRPI0613357A2
BRPI0613357A2 BRPI0613357A BRPI0613357A BRPI0613357A2 BR PI0613357 A2 BRPI0613357 A2 BR PI0613357A2 BR PI0613357 A BRPI0613357 A BR PI0613357A BR PI0613357 A BRPI0613357 A BR PI0613357A BR PI0613357 A2 BRPI0613357 A2 BR PI0613357A2
Authority
BR
Brazil
Prior art keywords
mmm
peptide
tgf
reducing
deposition
Prior art date
Application number
BRPI0613357A
Other languages
English (en)
Inventor
Agah Ramtin
Original Assignee
Agah Ramtin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agah Ramtin filed Critical Agah Ramtin
Publication of BRPI0613357A2 publication Critical patent/BRPI0613357A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BRPI0613357A 2005-06-24 2006-06-23 peptídeo, segmento amino- e/ou carboxila truncado do peptídeo, sequência de nucleotídeos, vetor de expressão, célula hospedeira, proteína de fusão, preparação farmaceuticamente pura, composição, método para estabilização da placa aterosclerótica e redução da ocorrência de eventos de ruptura de placa, método de redução de inflamação e de deposição de lipídeo e aumento de deposição de colágeno e elastina dentro da lesão intima, método de ativação de tgf-b1 e/ou desativação de mmm-9 e método para a modulação da atividade de tgf-b1 e/ou mmm-9 BRPI0613357A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69357405P 2005-06-24 2005-06-24
PCT/US2006/024692 WO2007002534A2 (en) 2005-06-24 2006-06-23 Thrombospondin-1 derived peptides and treatment methods

Publications (1)

Publication Number Publication Date
BRPI0613357A2 true BRPI0613357A2 (pt) 2017-02-21

Family

ID=37595929

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0613357A BRPI0613357A2 (pt) 2005-06-24 2006-06-23 peptídeo, segmento amino- e/ou carboxila truncado do peptídeo, sequência de nucleotídeos, vetor de expressão, célula hospedeira, proteína de fusão, preparação farmaceuticamente pura, composição, método para estabilização da placa aterosclerótica e redução da ocorrência de eventos de ruptura de placa, método de redução de inflamação e de deposição de lipídeo e aumento de deposição de colágeno e elastina dentro da lesão intima, método de ativação de tgf-b1 e/ou desativação de mmm-9 e método para a modulação da atividade de tgf-b1 e/ou mmm-9

Country Status (13)

Country Link
US (1) US8546323B2 (pt)
EP (1) EP1901761A4 (pt)
JP (1) JP2008543345A (pt)
KR (1) KR20080039878A (pt)
CN (1) CN101267829A (pt)
AU (1) AU2006261911B2 (pt)
BR (1) BRPI0613357A2 (pt)
CA (1) CA2613193A1 (pt)
EA (1) EA200800123A1 (pt)
IL (1) IL188310A0 (pt)
NO (1) NO20076603L (pt)
UA (1) UA94046C2 (pt)
WO (1) WO2007002534A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation
WO2012026614A1 (ja) * 2010-08-24 2012-03-01 国立大学法人宮崎大学 マトリックスメタロプロテアーゼ活性抑制組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434593D1 (de) * 1993-08-13 2006-02-02 Uab Res Foundation Birmingham Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta
US6458767B1 (en) * 1994-05-04 2002-10-01 The Uab Research Foundation Use of peptides inhibitory for thrombospondin dependent TGF-β activation in the treatment of kidney disease
US7220557B2 (en) 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
NZ516237A (en) * 1999-05-25 2004-03-26 Human Genome Sciences Inc Meth1 and meth2 polynucleotides and polypeptides
EP1325338A2 (en) * 2000-04-03 2003-07-09 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of alzheimer's disease
US20030134784A1 (en) * 2000-08-17 2003-07-17 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 83P2H3 and CaTrF2E11 useful in treatment and detection of cancer
US20030166017A1 (en) 2000-11-09 2003-09-04 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
DE60235413D1 (de) * 2001-12-07 2010-04-01 Novartis Vaccines & Diagnostic Bei prostatakrebs hochreguliertes endogenes retrovirus

Also Published As

Publication number Publication date
UA94046C2 (ru) 2011-04-11
WO2007002534A2 (en) 2007-01-04
WO2007002534A3 (en) 2007-12-06
CN101267829A (zh) 2008-09-17
IL188310A0 (en) 2008-04-13
EA200800123A1 (ru) 2008-12-30
CA2613193A1 (en) 2007-01-04
AU2006261911B2 (en) 2010-05-13
AU2006261911A1 (en) 2007-01-04
NO20076603L (no) 2008-03-17
JP2008543345A (ja) 2008-12-04
EP1901761A4 (en) 2009-08-12
US20090131314A1 (en) 2009-05-21
EP1901761A2 (en) 2008-03-26
US8546323B2 (en) 2013-10-01
KR20080039878A (ko) 2008-05-07

Similar Documents

Publication Publication Date Title
Rami et al. Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
Kuldeep et al. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata
WO2008148967A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
WO2008139122A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
WO2009003034A8 (en) Oligopeptide tyrosinase inhibitors and uses thereof
EP1571969A3 (en) Systems and methods for electrosurgical tissue treatment
AR039103A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas
ECSP099276A (es) Agente para prevenir/tratar el cancer
Argilés et al. Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
BR112012006389A2 (pt) agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo
CO5720000A2 (es) Derivados de macrolidos con actividad antiinflamatoria, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
AU2003258247A1 (en) Medical decision support systems utilizing gene expression and clinical information and method for use
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
ATE271036T1 (de) Perindoprilsalz und dieses enthaltende arzneimittel
AU2002330556A1 (en) Cosmetic or dermatological use of peptides for promoting adhesion between skin cells
WO2008139123A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
Toldo et al. Recombinant human alpha-1 antitrypsin-Fc fusion protein reduces mouse myocardial inflammatory injury after ischemia–reperfusion independent of elastase inhibition
BRPI0613357A2 (pt) peptídeo, segmento amino- e/ou carboxila truncado do peptídeo, sequência de nucleotídeos, vetor de expressão, célula hospedeira, proteína de fusão, preparação farmaceuticamente pura, composição, método para estabilização da placa aterosclerótica e redução da ocorrência de eventos de ruptura de placa, método de redução de inflamação e de deposição de lipídeo e aumento de deposição de colágeno e elastina dentro da lesão intima, método de ativação de tgf-b1 e/ou desativação de mmm-9 e método para a modulação da atividade de tgf-b1 e/ou mmm-9
NO20044639L (no) Farmasoytisk preparat for behandling av rhinitt
Bilic et al. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice
WO2006075095A3 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
Oldakovskiy et al. Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa
NO20071142L (no) Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 18070085223/SP DE 26/12/2007.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A EXIGENCIA CODIGO 6.7 PUBLICADA NA RPI NO 2138 DE 27/12/2011, POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.11 NA RPI NO 2423 DE 13/06/2017.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2408 DE 01/03/2017.